Guidance for Practicing Primary Care

Clinical Guidelines: Testosterone therapy in men with hypogonadism


 

Monitoring

Patients should be evaluated 3-6 months after initiating treatment to see whether symptoms have improved, to see whether there have been adverse reactions, and to check labs.

Serum testosterone should be checked and the dose of testosterone replacement should be adjusted to maintain the serum testosterone level in the mid-normal range for healthy young men. Serum testosterone should be drawn at different times for different formulations – for instance, it should be checked 2-8 hours following a gel application.

Hematocrit should be checked at baseline and 3-6 months into treatment. If hematocrit is greater than 54%, therapy should be held until hematocrit decreases and then restarted at a reduced dose. Screening for prostate cancer should be done if that was decided upon during discussion with the patient. Further urologic evaluation is indicated in men who, during the first year of treatment, develop an increase from baseline PSA greater than 1.4 ng/mL, have a repeat PSA over 4 ng/mL, or have a prostatic abnormality on digital rectal exam.

The bottom line

Hypogonadism is common and presents diagnostic challenges because of nonspecific signs and symptoms. Serum testosterone should be checked on a first-morning fasting specimen. Low testosterone concentrations need to be confirmed before making the diagnosis and should be followed by checking FSH and LH. For those with signs and symptoms of hypogonadism and persistently low testosterone, testosterone replacement therapy can be beneficial, with a goal of maintaining serum testosterone in the mid-range of normal.

Reference

Bhasin S et al. Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018 May;103(5):1-30.

Dr. Skolnik is a professor of family and community medicine at Jefferson Medical College, Philadelphia, and an associate director of the family medicine residency program at Abington (Pa.) Jefferson Health. Dr. Hurchick is a third-year resident in the family medicine residency program at Abington Jefferson Health.

Pages

Recommended Reading

Free testosterone linked to frailty in older men
MDedge Family Medicine
Without reliability, testosterone testing may fall short
MDedge Family Medicine
VIDEO: Researchers closing in on the elusive ‘male pill’
MDedge Family Medicine
MDedge Daily News: Stem cells may reverse premature menopause
MDedge Family Medicine
Sexual harassment, violence is our problem, too
MDedge Family Medicine
Declining androgen levels correlated with increased frailty
MDedge Family Medicine
MDedge Daily News: Can androgen therapy improve male frailty?
MDedge Family Medicine
VIDEO: Poorer cardiometabolic health seen in men with low sperm count
MDedge Family Medicine
Zika virus: Sexual contact risk may be limited to short window
MDedge Family Medicine
Transgender women on HT have lower bone density, more fat mass than men
MDedge Family Medicine